The startup develops biomimetic heart valve therapy using tissue-engineered polymeric scaffolds that mimic natural heart valve properties, providing durable, non-thrombogenic, and calcification-resistant solutions. Their proprietary Transcatheter Tricuspid Valve Replacement System, OneValveTRIC, offers a minimally invasive option for treating tricuspid valve regurgitation, catering to both older and younger patient populations with tailored valve regeneration capabilities.
Funding
$250K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current prosthetic heart valves, often made from metal or animal tissue, face limitations such as reduced long-term durability and the need for lifelong blood-thinning medication, increasing the risk of complications and repeat surgeries. Existing transcatheter tricuspid valve replacement (TTVR) options using animal-derived materials also present a high risk of thrombosis, especially in the heart's right side.
Solution
Neoolife is developing biomimetic polymeric heart valves using its proprietary Double Component Deposition (DCD) tissue engineering technology, which mimics the structure and function of native human heart valves. These non-animal-derived, metal-free valves are designed for long-lasting performance, resistance to calcification and thrombosis, and enhanced endogenous in-situ tissue regeneration. Their OneValveTRIC is a next-generation transcatheter tricuspid heart valve prosthesis that offers a minimally invasive solution for treating tricuspid valve regurgitation, with features such as an ultra-low-profile catheter and cardiac electrical conduction system management. The biomimetic design promotes endogenous tissue regeneration, potentially eliminating the need for lifelong anticoagulation.
Target Audience
The primary target audience includes cardiovascular surgeons and interventional cardiologists seeking durable, biocompatible heart valve replacement options, as well as patients with tricuspid regurgitation requiring minimally invasive treatment.
Features
- DCD technology engineers biomimetic polymeric scaffolds that mimic the structure and function of human heart valves.
- Non-animal-derived and metal-free construction eliminates transmission risks and supply security concerns.
- Available in both non-resorbable (permanent) and resorbable options for tailored valve regeneration capabilities.
- OneValveTRIC offers an ultra-low-profile catheter for ease of delivery and anatomical positioning.
- Designed to enhance endogenous in-situ tissue regeneration for improved long-term durability.
- Resistant to calcification and thrombosis, reducing the need for blood-thinning medication.
- Manufacturing process incorporates robotic technology for high precision and customization.